Adult Dosing

Prevention of rebleeding of esophageal varices

• Administer 1.5-5 mL per varix using IV sclerotherapy; Max: 20 mL per session
• For obliteration of the varix, administer injections during acute bleeding episode, and then at 1 wk, 6 wks, 3 months, and 6 months, as indicated

Note:

• Injection should be administered only by physicians familiar with sclerotherapy procedure
• Do not administer submucosally to avoid risk of ulceration

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Prevention of rebleeding in patients with esophageal varices that have recently bled

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Child-Pugh Class C: Reduce maximum dose

• Use of ethanolamine oleate in pregnant women is justified only if clearly required
• Ethanolamine oleate is not indicated for treatment of varicosities of the leg due to insufficient supportive clinical trial data
• Fatal anaphylactic shock may occur with administration of a larger than normal dose. Physicians should be equipped for emergency treatment of anaphylactic reaction
• Severe injection necrosis may occur with direct injection of high volumes of sclerosing agents
• Submucosal administration is not recommended due to risk of ulceration at the injection site

Caution: Use cautiously in

• Hepatic impairment
• Concomitant cardiorespiratory disease
• Elderly patients

Pregnancy Category:C

Breastfeeding: It is unknown if ethanolamine is excreted in breast milk. Manufacturer advises caution when administering to nursing mothers.

• GI: Esophageal ulcer, esophageal stricture
• GU: Acute renal failure
• HEMA: Bacteremia
• RESP: Pleural effusion/infiltration, pneumonia, aspiration pneumonia
• HYPERSENSITIVITY: Anaphylactic shock
• MISC: Pyrexia, retrosternal pain

• Sclerosing agent; irritates the intimal endothelium of the vein, thereby producing a dose-related inflammatory response. This results in fibrosis and possible occlusion of the vein
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Ethamolin

US Availability

Ethamolin

• INJ: 50 mg/mL (2 mL ampule)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• Only generic available

UK Availability

ethanolamine oleate (generic)

• INJ: 0.910%/4.23% w/v (ethanolamine/oleic acid)

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Cardiovascular

Sclerosing Agent